omeprazole has been researched along with ENT Diseases in 3 studies
Omeprazole: A 4-methoxy-3,5-dimethylpyridyl, 5-methoxybenzimidazole derivative of timoprazole that is used in the therapy of STOMACH ULCERS and ZOLLINGER-ELLISON SYNDROME. The drug inhibits an H(+)-K(+)-EXCHANGING ATPASE which is found in GASTRIC PARIETAL CELLS.
omeprazole : A racemate comprising equimolar amounts of (R)- and (S)-omeprazole.
5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole : A member of the class of benzimidazoles that is 1H-benzimidazole which is substituted by a [4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl group at position 2 and a methoxy group at position 5.
| Excerpt | Relevance | Reference |
|---|---|---|
| "However, the case that GERD is the cause of these symptoms is difficult to make because neither endoscopy nor prolonged reflux monitoring has shown consistent evidence of either esophageal injury or abnormal reflux frequency." | 2.43 | State of the art: extraesophageal manifestations of gastroesophageal reflux disease. ( Katz, PO, 2005) |
| "Gastroesophageal reflux disease (GERD) is present in up to 75% of patients with chronic refractory ear, nose, and throat (ENT) symptoms, and proton pump inhibitor (PPI) therapy induces symptom relief in the majority of these patients." | 1.33 | Determinants of long-term outcome of patients with reflux-related ear, nose, and throat symptoms. ( Feenstra, L; Poelmans, J; Tack, J, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Katz, PO | 2 |
| Poelmans, J | 1 |
| Feenstra, L | 1 |
| Tack, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Open Label, Randomized, Single Site Clinical Trial To Compare The Safety Of Herbal Melanin Extracted From Nigella Sativa Seeds Vs Standard Of Care Treatment In Treating Gastritis Patients[NCT03428568] | Phase 2 | 132 participants (Anticipated) | Interventional | 2018-03-31 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for omeprazole and ENT Diseases
| Article | Year |
|---|---|
State of the art: extraesophageal manifestations of gastroesophageal reflux disease.
Topics: Clinical Trials as Topic; Enzyme Inhibitors; Gastroesophageal Reflux; Humans; Lung Diseases; Omepraz | 2005 |
Gastroesophageal reflux disease and extraesophageal disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Asthma; Benzimidazoles; Esophageal pH Mo | 2005 |
1 other study available for omeprazole and ENT Diseases
| Article | Year |
|---|---|
Determinants of long-term outcome of patients with reflux-related ear, nose, and throat symptoms.
Topics: Anti-Ulcer Agents; Endoscopy, Gastrointestinal; Female; Follow-Up Studies; Gastroesophageal Reflux; | 2006 |